Tanzania WASH sector stakeholders collaborated between March and May 2022 to develop this Country WASH M&E Roadmap. The initial vision, outcomes and activities outlined in the Roadmap were established during a workshop, held on 2–3 March 2022, and further refined during a second workshop, held on ...28 April 2022.
more
This case study uses the Astana Primary Health Care (PHC) framework to explore the impact of the 2020–21 pandemic on primary health care in Kenya. While the pandemic exposed systemic challenges, such as limited testing capacity, an inadequate supply of PPE, and weak social protection, Kenya's heal...th system also demonstrated notable adaptability. The response was largely hospital-centred, with PHC playing a secondary role. Nevertheless, innovations emerged on both the provider and consumer sides to maintain service delivery and access. The study emphasises the importance of building on these experiences to enhance emergency preparedness and develop a more robust and integrated health system.
more
Poverty and associated health, nutrition, and social factors prevent at least 200 million children in developing countries from attaining their developmental potential. We review the evidence linking compromised development with modifiable biological and psychosocial risks encountered by children fr...om birth to 5 years of age. We identify four key risk factors where the need for intervention is urgent: stunting, inadequate cognitive stimulation, iodine deficiency, and iron deficiency anaemia. The evidence is also sufficient to warrant interventions for malaria, intrauterine growth restriction, maternal depression, exposure to violence, and exposure to heavy metals. We discuss the research needed to clarify the effect of other potential risk factors on child development. The prevalence of the risk factors and their effect on development and human potential are substantial. Furthermore, risks often occur together or cumulatively, with concomitant increased adverse effects on the development of the world's poorest children.
more
Malaria and HIV, two of the world’s most deadly diseases, are widespread, but their distribution overlaps greatly in sub-Saharan Africa. Consequently, malaria and HIV coinfection (MHC) is common in the region. In this paper, pertinent publications on the prevalence, impact, and treatment strategie...s of MHC obtained by searching major electronic databases (PubMed, PubMed Central, Google Scholar, ScienceDirect, and Scopus) were reviewed, and it was found that the prevalence of MHC in SSA was 0.7%–47.5% overall. Prevalence was 0.7%–47.5% in nonpregnant adults, 1.2%–27.8% in children, and 0.94%–37% in pregnant women. MHC was associated with an increased frequency of clinical parasitemia and severe malaria, increased parasite and viral load, and impaired immunity to malaria in nonpregnant adults, children, and pregnant women, increased in placental malaria and related outcomes in pregnant women, and impaired antimalarial drug efficacy in nonpregnant adults and pregnant women. Although a few cases of adverse events have been reported in coinfected patients receiving antimalarial and antiretroviral drugs concurrently, available data are very limited and have not prompted major revision in treatment guidelines for both diseases. Artemisinin-based combination therapy and cotrimoxazole are currently the recommended drugs for treatment and prevention of malaria in HIV-infected children and adults. However, concurrent administration of cotrimoxazole and sulfadoxine–pyrimethamine in HIV-infected pregnant women is not recommended, because of high risk of sulfonamide toxicity. Further research is needed to enhance our understanding of the impact of malaria on HIV, drug–drug interactions in patients receiving antimalarials and antiretroviral drugs concomitantly, and the development of newer, safer, and more cost-effective drugs and vaccines to prevent malaria in HIV-infected pregnant women.
more
The emergence of SARS-CoV-2 has significantly altered the epidemiology of other infectious diseases, making investigations into its co-infection with malaria particularly relevant in endemic regions. This review examines the epidemiological, incubation and clinical features of the two diseases, high...lighting the diagnostic challenges and strategies for accurate detection. Emerging immunological and genetic evidence indicates that prior exposure to malaria may reduce the severity of outcomes of SARS-CoV-2 infection through mechanisms involving ACE2 downregulation, TLR signalling, T-cell activation and upregulation of coinhibitory receptors. Additionally, potential control measures are discussed, including vaccine development, the repurposing of antimalarial drugs, the exploration of natural products, innovations in bioinsecticides, and the strengthening of electronic disease surveillance. These insights provide valuable guidance for clinical management and public health policy, while emphasising the need for continued research into the complex interactions between SARS-CoV-2 and malaria.
more
The annual bulletin of the Mekong Malaria Elimination (MME) programme is a yearly report that reviews ongoing efforts to combat multidrug resistance and eliminate malaria in the 6 countries of the Greater Mekong subregion (GMS): Cambodia, China (Yunnan province), Lao People's Democratic Republic, My...anmar, Thailand and Viet Nam.
more
Lesotho’s Social and Behaviour Change Communication Strategy is a strategic response to the high levels of HIV and TB prevalence in the country that are exacerbated by the persistence of structural and sio-economic difficulties, such as poverty, unemployment, gender inequality and more. This strat...egy aims to address these issues.
more
20 YEARS OF STRATEGIC HIV AND PUBLIC HEALTH DATA . beThe completion of the 6th South African National HIV Prevalence, Incidence and Behaviour Survey (SABSSM) report, coincides with the celebration of 30 years of democracy in South Africa; and marks 20 years of conducting nationally representative ho...usehold-based surveys by the Human Sciences Research Council (HSRC), its collaborators and donors. Since its inception in 2002, the SABSSM series has emerged as one of the HSRC’s leading scientific contributions to the country’s HIV and AIDS response (1), providing essential data to monitor the HIV epidemic, the impact of the HIV program in South Africa, and to inform strategies for epidemic control in the National Strategic Plan for HIV, TB and STIs (NSP), now in its fifth edition. Using scientific evidence from SABSSM and other key sources, the NSP guides the country’s response, under the leadership of the South African AIDS Council (SANAC) and the National Department of Health (NDoH), with focus on equitable access to biomedical interventions, addressing the structural and social behavioural drivers of the epidemic, and targeting populations disproportionately affected by HIV; such as, black Africans, key populations and adolescent girls and young women (AGYW) aged 15–24 years (2).
more